Menu
SI-BONE is a medical device company that pioneered minimally invasive surgery of the SI joint with the iFuse Implant System. Studies have shown that the SI joint can be a source of pain in 15% to 30% of chronic low back pain. The iFuse Implant™, commercially available since 2009, is the only SI joint fusion device supported by multiple prospective clinical studies, including two randomized controlled trials, showing improved pain, patient function and quality of life resulting from treatment. There are over 90 peer-reviewed publications demonstrating the safety, durable effectiveness, and biomechanical and economic benefits unique to the iFuse Implant (www.si-bone.com/results). This body of evidence has enabled multiple government and private insurance payors to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System.
471 El Camino Real Ste 101
Santa Clara, California 95050-4482
Phone: 14082070700
si-bone.com
SI-BONE Inc (NASDAQ: SIBN ) reported a Q4 EPS loss of $(0.32) , beating the consensus of $(0.40) and sales of $31.95 million, slightly ahead of the consensus of $31.22 million. Refinanced existing $35 million term loan with a new $51 million credit facility, including a $36 million term loan and a $15 undrawn revolving credit facility The company reported over 920 active surgeons in the fourth quarter of 2022, up 33% Y/Y. It surpassed 80,000 procedures performed by over 3,000 surgeons worldwide. SI-BONE sees 2023 revenues of $124-$127 million compared to the … Full story available on Benzinga.com
SI-BONE, Inc. (NASDAQ:NASDAQ:SIBN) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ETCompany ParticipantsSaqib Iqbal - Director of Investor RelationsLaura Francis - Chief…
The following slide deck was published by SI-BONE, Inc.
Gainers: Progyny (PGNY) +14%. SI-BONE (SIBN) +12%. AAON (AAON) +8%
SANTA CLARA, Calif. (AP) — SANTA CLARA, Calif. (AP) — Si-Bone Inc. (SIBN) on Monday reported a loss of $11.2…
SI-BONE press release (SIBN): Q4 GAAP EPS of -$0.32 beats by $0.07.Revenue of $31.95M (+26.8% Y/Y) beats by $0.18M.Adjusted EBITDA loss improved in the fourth quarter 2022 by 54%…
SI-BONE (NASDAQ: SIBN ) is set to give its latest quarterly earnings report on Monday, 2023-02-27. Here''s what investors need to know before the announcement. Analysts estimate that SI-BONE will report an earnings per share (EPS) of $-0.40. SI-BONE bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next … Full story available on Benzinga.com
SANTA CLARA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the fourth quarter of 2022 after market close on Monday, February 27, 2023. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.